In Houston, on April 3, 2026, Impact BioMedical Inc. (NYSE American: IBO) disclosed in its annual report (10-K) for the fiscal year that ended on December 31, 2025, filed on March 11, 2026, that the audit opinion from Grassi & Co., CPAs, P.C. includes a "going concern" qualification. This disclosure was made in accordance with NYSE American LLC Company Guide Section 610(b), which mandates public announcement of receiving an audit opinion with a going concern paragraph. Importantly, this does not indicate any modifications to the Company’s financial statements for the year terminated on December 31, 2025.